,,ib ,union ,calendar ,no4 #dca #aadth ,,congress #b;d ,session ,h4 ,r4 #digf ,report ,no4 #aad-eeg ,,in ,,the ,,house ,,of ,,representatives ,april #ah1 #bjaf ,mr4 ,sean ,patrick ,maloney of ,new ,york 7for himself and ,mr4 ,lance7 introduced the following bill2 which was referred to the ,committee on ,energy and ,commerce ,may #aj1 #bjaf ,committed to the ,committee of the ,whole ,house on the ,state of the ,union and ordered to be printed ,a ,,bill ,to require the ,commissioner of ,food and ,drugs to seek recommendations from an advisory committee of the ,food and ,drug ,administration before approval of certain new drugs that are opioids without abuse-deterrent properties1 and for other purposes4 #a4 ,short title ,this ,act may be cited as the ,opioid ,review ,modernization ,act of #bjaf4 #b4 ,,fda opioid action plan ,chapter ,v of the ,federal ,food1 ,drug1 and ,cosmetic ,act is amended by inserting after section #efi of such ,act 7#ba ,u4,s4,c4 #cej;bbb-#h7 the following3 #efi-a4 ,opioid action plan 7a7 ,new drug application 7#a7 ,in general ,subject to paragraph 7#b71 prior to the approval pursuant to an application under section #eje7;b7 of a new drug that is an opioid and does not have abuse-deterrent properties1 the ,secretary shall refer the application to an advisory committee of the ,food and ,drug ,administration to seek recommendations from such advisory committee4 7#b7 ,public health exemption ,a referral to an advisory committee under paragraph 7#a7 is not required with respect to a new drug if the ,secretary-- 7,a7 finds that such a referral is not in the interest of protecting and promoting public health2 7,b7 finds that such a referral is not necessary based on a review of the relevant scientific information2 and 7,c7 submits a notice containing the rationale for such findings to the ,committee on ,health1 ,education1 ,labor1 and ,pensions of the ,senate and the ,committee on ,energy and ,commerce of the ,house of ,representatives4 7b7 ,pediatric opioid labeling ,the ,secretary shall convene the ,pediatric ,advisory ,committee of the ,food and ,drug ,administration to seek recommendations from such ,committee regarding a framework for the inclusion of information in the labeling of drugs that are opioids relating to the use of such drugs in pediatric populations before the ,secretary approves any labeling or change to labeling for any drug that is an opioid intended for use in a pediatric population4 7c7 ,sunset ,the requirements of subsections 7a7 and 7b7 shall cease to be effective on ,october #a1 #bjbb4 4 #c4 ,prescriber education ,not later than #a year after the date of the enactment of this ,act1 the ,secretary of ,health and ,human ,services1 acting through the ,commissioner of ,food and ,drugs1 as part of the ,food and ,drug ,administration's evaluation of the ,extended-,release_/,long-,acting ,opioid ,analgesics ,risk ,evaluation and ,mitigation ,strategy1 and in consultation with relevant stakeholders1 shall develop recommendations regarding education programs for prescribers of opioids pursuant to section #eje-a of the ,federal ,food1 ,drug1 and ,cosmetic ,act 7#ba ,u4,s4,c4 #cee-a71 including recommendations on-- 7#a7 which prescribers should participate in such programs2 and 7#b7 how often participation in such programs is necessary4 #d4 ,guidance on evaluating the abuse deterrence of generic solid oral opioid drug products ,not later than #b years after the end of the period for public comment on the draft guidance entitled ,general ,principals for ,evaluating the ,abuse ,deterrence of ,generic ,solid ,oral ,opioid ,drug ,products issued by the ,center for ,drug ,evaluation and ,research of the ,food and ,drug ,administration in ,march #bjaf1 the ,commissioner of ,food and ,drugs shall publish in the ,federal ,register a final version of such guidance4 ,may #aj1 #bjaf ,committed to the ,committee of the ,whole ,house on the ,state of the ,union and ordered to be printed